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ABSTRACT 
Objective: The therapeutic equivalence of generic brands is a great challenge for manufacturers. This study aimed to evaluate the bioequivalence of 
four different generic brands of atenolol tablets under biowaiver conditions. 
Methods: Physiochemical properties of the tablet products namely uniformity of weight, hardness, disintegration, and drug content were assessed. 
The dissolution profiles of atenolol tablets were conducted in pH 1.2, 4.5, 6.8 and 7.6 buffers using USP dissolution apparatus II. Similarity and 
difference factors were calculated. Finally, four kinetic models have been offered to describe the release characteristics of atenolol under 
experiment conditions. 
Results: All tablets showed accepted physiochemical characters. Dissolution profiles revealed that G2 showed the highest similarity to innovator (f2 
91.86) in pH 7.6. Dissolution kinetics of G2 at the same pH could be best described as Higuchi model of release.  
Conclusion: The study showed that excipients and manufacturing practices play an important role in marketing biowaiver generic products meet 
the international regulatory bodies criteria. 
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INTRODUCTION 
Proving similarity precisely in terms of efficacy and safety between 
innovator products and generic ones is an important step in granting 
authorization for marketing the generic products. Manufacturing 
variations including excipients, manufacturing process, types of 
equipment, work conditions and batches size can show variations in 
the bioavailability of the drug [1, 2]. In vivo bioavailability studies 
are amended for marketing the generic products [3]. Bioavailability 
studies conducted in animals or humans are time and money 
consuming [4, 5]. Today many regulatory authorities and 
organizations like the Food and Drug Administration (FDA) and the 
World Health Organization (WHO) accept wavier of in vivo 
bioequivalence studies using in vitro release dissolution data for 
immediate release oral solid dosage form for drugs from 
Biopharmaceutical Classification System (BSC) Class I and Class III 
drugs [1, 6-10]. Dissolution studies are easier, cheaper, less time 
consuming than in vivo studies in addition to its conduction in vitro, 
therefore it is an encouraging substitute to in vivo studies [11, 12]. 
Biowaiver studies are usually applied to approve that the safety and 
efficacy of two or more products are accepted based on confirmation 
of equivalence other than through in vivo testing [13-15]. It also 
permits the setting of the required conditions of the dissolution test 
[16, 17]. Atenolol is one of the cardio selective b-blocker drugs, 
which is widely used in the managing of hypertension, angina 
pectoris, cardiac arrhythmias, and myocardial infarction. It was 
listed as an essential medicine in the WHO model list of essential 
medicines [18]. On a Pharmaceutical base; Atenolol is classified as 
Class III drug; it can be defined as slightly soluble in water [19-21]. 
The solubility of atenolol was evaluated in different pH values; 
different solubility was shown at different pH media as reported by 
Vogelpoel H. in 2004 [22]. Many drugs in Class III have been 
reported as models for biowaiver studies [23, 24]. The study aimed 
to evaluate the bioequivalence of four different generic brands of 
atenolol tablets under biowaiver conditions, in vitro dissolution test 
were conducted for four generic products of atenolol immediate-
release tablet in the market mentioned as G1, G2, G3 and G4 in 
comparison to innovator brand (Tenormin® 50) in four different pH 
media (1.2, 4.5, 6.4 and 7.5). In addition, four kinetic models Zero-
order, First-order, Hixson-Crowell, and Higuchi model have been 
proposed to describe the release features of a drug from tablets 
formula under investigation conditions. 
MATERIALS AND METHODS 
Materials 
Reference Atenolol was a kind gift sample from (Tabouk Co., KSA). Four 
generic brands of atenolol 50 mg tablets (G1, G2, G3 and G4) and 
Innovator brand (IB) Tenormin®50 mg (AstraZeneca, United Kingdom) 
were purchased from a registered pharmacy. Hydrochloric acid (Loba 
Chemie Pvt. Ltd, India), acetic acid (BDH Chemicals LTD Poole, England), 
sodium acetate (BDH Prolanbo, England), potassium chloride 
(Avonchem limited, UK), potassium dihydrogen orthophosphate (Loba 
Chemie Pvt. Ltd, India), sodium hydroxide (May and Baker LTD, 
Bahenham, England), methanol (Sigma-Aldrich, USA). 
Methods 
Characterization of physiochemical parameters  
Physiochemical properties of the tablet products namely uniformity 
of weight, hardness, disintegration test, and drug content were 
assessed according to United States Pharmacopeia [25]. 
Preparation of different buffer media 
The buffer media used in the study (0.1N HCL and buffer pH 4.5, 6.8 
and 7.6 were prepared based as mentioned in British 
Pharmacopoeia [26]. 
Ultraviolet scanning of atenolol in different pH media 
Stock solutions of atenolol in methanol and the previously 
mentioned buffer media were scanned spectrophotometrically and 
the wavelength for maximum absorbance under experiment 
conditions was determined. The precision of the method was 
verified by inter-day and intra-day variation studies. 
Preparation of standard calibration curves 
Gradient atenolol standard concentrations ranged between 20 and 
200 μg/ml were prepared from stock solutions and subjected to Ultra-
violet spectrophotometric method at the predetermined maximum 
wavelength. Respective absorbances were recorded and lines of 
regression were plotted. The calibration made in methanol was used 
for content determination while that in 0.1N HCl, Buffer pH 4.5, 6.8 and 
7.6 were used for the dissolution studies of the sample tablets. 
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Drug content assay 
Ten tablets of each product were weighed to define the average 
weight. The tablets were powdered into a fine powder. The weight 
equivalent to 50 mg of atenolol was transferred to 100 ml 
volumetric flask, 100 ml of methanol was added and the solution 
was sonicated for 30 min. The resulting solution was filtered 
through Whatman filter paper 45 µm, and 2 ml of the filtrate was 
transferred to a 10 ml volumetric flask and diluted with methanol to 
10 ml, 0.01% w/v of atenolol was obtained. The absorbance of the 
solution was measured by a UV/visible spectrophotometer and the 
concentrations of atenolol were determined from the calibration 
standard curve. The experiment was performed in triplicate for each 
brand; mean values and standard deviation were calculated [27]. 
Dissolution study 
The dissolution profiles of atenolol tablets were assessed in 900 ml 
of 0.1NHCl and buffer pH4.5, 6.8 and 7.6 using an eight-station USP 
dissolution apparatus II (VK 7020 Vankel®, Canada). The 
temperature was kept as 37 °C±0.5 and 75 rpm. Five-milliliter 
samples were collected at predetermined time intervals 5, 10, 15, 30, 
45 and 60 min. Five ml of fresh medium pre-warmed to 37 °C was 
replaced into dissolution medium after each sampling to maintain 
sink condition requirements. All samples were filtered using 
Whatman filter paper 45 µm and were assessed using a UV/VIS 
spectrophotometer at 273 nm. The experiment was carried out in 
triplicate and the mean values were plotted versus time. All results 
were stated as the percentage of the cumulative amount of drug 
released (%) as a function of time [28]. 
Analysis of data 
The results of uniformity of weight, hardness, disintegration and 
drug content simple were analyzed and results were expressed as 
mean±standard deviation. The dissolution profile differences were 
assessed based on the similarity factor (f2) and the difference factor 
(f1) as:  
f2 = 50 ∗ log{[1 + �1
n
� ∑(Rt − Tt)2]− 0.5 ∗ 100} (1) 
f2; similarity factor and Rt and Tt are percent dissolved at each time 
point for reference and test products respectively. f2 Values of 50 or 
higher (50-100) confirm the similarity of the products. 
f1 = [∑ | Rt − Tt|/∑Rt] ∗ 100 (2) 
f1 value of 0 to 15 confirms a slight difference between two 
products-Guidance, F. D. A, 2000 [7, 29]. 
Model dependent in vitro release characterization 
Four kinetic models have been offered to describe the release 
characteristics of atenolol from different brands under experiment 
conditions [30-33].  
Zero order:  
Qt = Qo + kot (3) 
Where Qt is the amount of drug released at time t, Q0 is the initial 
concentration of drug and k0 is the zero-order release rate constant. 
The cumulative amount of drug released was plotted versus time. 
First order:  
log Qt =  log Qo− kt/2.303 ……. (4) 
Where Qt is the amount of drug remaining as a solid-state at time t, 
Qo is the initial concentration of drug and k is the first-order release 
rate constant. The data obtained were plotted as log cumulative 
percentage of drug remaining versus time which would yield a 
straight line with a slope of–k/2.303.  
Hixson-crowell model:  
M0
1/3 −  Mt
1
3 = Kt ……. (5) 
M0 is the initial amount of drug in the pharmaceutical dosage form, 
Mt is the remaining amount of drug in the pharmaceutical dosage 
form at a time‘t’ and κ is proportionality constant. 
Higuchi model:  
Qt = kt1/2 ……. (6) 
Where Qt is the amount of drug released in time t, and k is the 
Higuchi's release rate constant. The data obtained were plotted as 
cumulative percentage drug release versus square root of time. 
RESULTS AND DISCUSSION 
Physical characterization  
Four generic brands G1, G2, G3, and G4 of atenolol immediate-
release tablets were assayed in comparison to the innovator brand 
(IB). For tablet weight variation, friability, disintegration, hardness, 
and content tests, all products comply with the Pharmacopeial 
specification of immediate release dosage forms. Friability test 
showed that the highest loss in weight was 0.16 for G3. Tablets 
hardness was within the satisfactory limit (between 4.55–6.12 
kg/cm2), the difference in tablet strength between the lowest (G3) 
and highest (IB) strength was 1.57 kg/cm2, this difference could be 
interoperated on the base of difference in weight between tablets 
which give them different ability to absorb crushing force. All 
generic tablets' strength showed a significant difference compared 
with the innovator at p-value<0.05. Although tablet strength is 
essential to withstand handling and packaging steps it should not 
affect the drug’s dissolution adversely. The tablets' uniformity of 
weight showed low variation (less than±3.0%). G2 weight was the 
lowest while G3 was the highest average weight (table 1). 
Calibration curves plotting of atenolol in different pH media 
Spectrums scan for Atenolol standard solution in four different pH 
mediums 1.2, 4.5, 6.8, and 7.6 were performed in a range between 
200-400 nm. It showed a maximum wavelength absorption (λmax) at 
273 nm for all media as shown in fig. 1. 
 
 
Fig. 1: UV Spectrum scan for Atenolol standard in pH 6.8 medium 
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Linear equations in different media were shown as following:  
y = 0.0049x R² = 0.9998 in 0.1N Hcl 
y = 0.0046x + 0.007 R² = 0.9998 in 4.5 pH buffer media 
y = 0.0047x R² = 0.9999 in 6.8 pH buffer media 
y = 0.0075x − 0.001 R² = 0.9992 in 7.6 pH buffer media 
Where y and x are the absorbance and the concentration respectively.
 
Table 1: Physicochemical characteristics of selected brands of atenolol tablets in comparison to IB 
Brand Uniformity of weight (%)  Friability (%) Disintegration Hardness Content assay (%) 
G1 210.72±1.14 0.06 4.61±0.59 4.72±0.23 99.77±0.399 
G2 177.21±1.65 0.02 3.47±0.32 5.23±1.52 99.30±0.260 
G3 220.87±2.75 0.16 5.44±0.25 4.55±1.34 100.13±0.756 
G4 189.48±2.59 0.03 3.25±0.31 5.24±0.96 101.16±0.715 
IB 210.065±1.98 0.03 2.39±0.12 6.12±1.22 100.69±4.23 
Weights in mg, disintegration time in minutes, hardness in Kg/cm2, all results except friability expressed as mean±SD 
 
Drug content assay 
The content uniformity results are shown in table 1. All tablet 
samples were complying with pharmacopeial limits, i.e. the average 
drug content of all samples was within the range of 85% to 115% of 
the label statement.  
Dissolution studies 
The dissolution profiles are shown in fig. 2-5 in four dissolution 
medium at pH 1.2,4.5, 6.8, and 7.6. The statistical result of similarity 
factor (f2) and the difference factor (f1) is showed in table 2, the 
innovator brand was used as a reference. In hydrochloric acid buffer 
pH 1.2 all generic brands G1, G2, G3, and G4 met innovator 
requirement with similarity factor 64.90, 71.76, 69.69 and 55.99 
respectively. The difference factors were 5.58, 3.46, 4.02, and 6.73 
respectively but none of the brands including the innovator released 
more than 85% of API in 15 min. All the products meet the WHO 
requirement for class III bio wavier in acetate buffer pH 4.5 as all 
released more than 85% of API in 15 min while merely G2 crossed 
similarity factor f2=68.16. In contrast, the release of the drug in 
phosphate buffer pH 6.8 revealed that only G2 and G4 meet the WHO 
requirements. G1andG2 only showed a similarity factor of more than 
50 ie. 58.25 and 59.15 respectively. The dissolution pattern of the IB, 
G2, G3, and G4 in phosphate buffer pH 7.6 is less than 66% in 60 min 
which indicates the poor release of API in slightly alkaline pH media. 
Only G1 released more than 85% of the drug in 30 min which may be 
due to the type of excipient and manufacturing process. From the 
results of dissolution profile in this study it observable that G2 is 
mostly similar to the innovator, and it released more than 85% of 
API in 15 min in buffer pH 6.8 and buffer pH4.5 and crossed 
similarity factor in all pH medium so it can be considered as 
bioequivalent with the IB under experiment conditions. The 
dissolution profiles of different products under investigation did not 
show a correlation between the strength and dissolution of tablets. 
ANOVA test results showed that different tablets had different 
strengths (p<0. 01). IB and G3 which had different strength values 
(table 1), had more than 85% of the drug released within 15 min. 
This is in well agreement with others finding that not only the 
manufacturing conditions but also formula factors, such as 
disintegrates and diluents types and quantity, play an important part 
in the breaking of tablet and dissolution profiles. Based on biowaiver 
study results, samples G1, G2, and G3 are not bioequivalent with the 
IB unless further an in vivo bioequivalent studies prove that. Also 
Reddy, N. H., et al., published that some but not all Acyclovir, 
Atenolol, and Ciprofloxacin Hydrochloride products met the 
biowaiver criteria [20]. Excipients and additives used in 
manufacturing tablets have great effects on their dissolution, 
therefore to achieve biowaiver according to regulatory rules, good 
manufacturing practice should be followed and careful selection of 
the excipients used is mandatory. 
 
Table 2: Dissolution data comparison for G1, G2, G3, and G4 in comparison to IB in different pH media using similarity (f2) and difference 
factor (f1) 




64.90 71.76 69.69 59.99 
5.58 3.46 4.02 6.73 
pH 4.5  
f2 
f1 
48.42 68.16 49.045 38.055 
10.26 3.64 4.404 9.286 
pH 6.8  
f2 
f1 
58.28 59.15 40.775 49.18 
6.73 7.26 9.366 11.332 
pH 7.6  
f2 
f1 
26.10 91.86 70.77 72.71 
33.39 1.48 4.867 4.967 
 
Model of in vitro release characterization 
Various release models were applied to study the release kinetics 
and mechanism of drug release from different sample tables as 
shown in table 3 and fig. 6-9. 
To study the dissolution kinetics and the mechanism of drug release 
for the five commercial brands of atenolol used in this study, four 
models were used, namely, Zero-order, Firs-order, Hixson-Crowell, 
and Higuchi models. 
Table 3, showed that the dissolution kinetic of G2 at pH = 1.2 was 
best described by a zero-order equation with r2 equal to 0.965 and 
that the mechanism of release was best described by the Higuchi 
equation (r2= 0.942) which indicate that the release was diffusion 
controlled. By changing the pH of the dissolution medium, the 
dissolution kinetics for G2 was changed from zero-order to first-
order kinetics at pH = 7.6 while the dissolution mechanism remained 
to be diffusion controlled. At pH 4.5 and 6.8, the mechanism of 
release was changed from a diffusion-controlled to dissolution 
controlled with an increase in the r2 values for the Hixson-Crowell 
model. G1 at pH 1.2 showed first-order kinetics and the mechanism 
of release was dissolution controlled while at pH 6.8 the dissolution 
mechanism was changed to diffusion control. The four models used 
in this study did not apply to the dissolution data obtained for G3 
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and G4 with r2 values less than 0.90 at all pH used in this study. The 
dissolution data for IB at pH 1.2 showed that the dissolution kinetics 
followed zero-order kinetics and the mechanism of drug release was 
diffusion controlled and that the change in the pH value from 1.2 to 
6.8 and 7.6 was no change the dissolution kinetics as well as in the 
mechanism of release. Results revealed that the faster rate constant 
for all brands was at pH 4.5 and the slowest rate constant for all 
brands was at pH 7.6. 
 
 
Fig. 2: Dissolution profiles of IB, G1, G2, G3 and G4 tablets at pH 1.2 dissolution medium (n=3±SD) 
 
 
Fig. 3: Dissolution profiles of IB, G1, G2, G3 and G4 tablets at pH 4.5 dissolution medium (n=3±SD) 
 
 
Fig. 4: Dissolution profiles of IB, G1, G2, G3 and G4 tablets at pH 6.8 dissolution medium (n=3±SD) 
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Fig. 5: Dissolution profiles of IB, G1, G2, G3 and G4 tablets at pH 7.6 dissolution medium (n=3±SD) 
 
 
Fig. 6: Dissolution data at pH = 1.2 according to zero-order (A), First order (B), Hixson equation (C) and Higuchi equation (D), for IB (◊), 
G1 (X), G2 (ж), G3 (∆), and G4 (□) 
 
 
Fig. 7: Dissolution data at pH = 4.5 according to zero-order (A), First order (B), Hixson equation (C) and Higuchi equation (D), for IB ( ◊), 
G1 (X), G2 (ж), G3 (∆), and G4 (□) 
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Fig. 8: Dissolution data at pH = 6.8 according to zero-order (A), First order (B), Hixson equation (C) and Higuchi equation (D), for IB (◊), 
G1 (X), G2 (ж), G3 (∆), and G4 (□) 
 
 
Fig. 9: Dissolution data at pH = 7.6 according to zero-order (A), First order (B), Hixson equation (C) and Higuchi equation (D), for for IB 
(◊), G1 (X), G2 (ж), G3 ( ∆), and G4 (□) 
 
CONCLUSION 
Monitoring the generic product protects the patient from 
therapeutic failure and decrease the cost of the health care system. 
Biowaiver study is an easy and less time-consuming way for 
evaluating the equivalence of generic drugs to the innovator drug. 
The in vitro dissolution profile in our study showed that one generic 
brand has observable similarity with the innovator brand and it can 
be interchangeable with it. Excipients and manufacturing practice 
play an important role in marketing biowaiver generic drug 
products meet the international regulatory bodies criteria.  
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